Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Former Hedge Fund Executive Charged By SEC
- By Svea Herbst-BaylissBOSTON (Reuters) - A former top executive at hedge fund firm ValueAct Capital is one of seven people charged with trading on inside information in Acxiom Corp.Ronald Yee, who had been the San Francisco-based hedge fund firm's chief financial officer until June 2008, was named in a civil...
- News items 2009-10-31
- Former U.S. Hedge Fund Exec Charged
- By Svea Herbst-BaylissBOSTON (Reuters UK) - A former top executive at hedge fund firm ValueAct Capital is one of seven people charged with trading on inside information in Acxiom ACXM.Ronald Yee, who had been the San Francisco-based hedge fund firm's chief financial officer until June 2008, was named in a...
- News items 2009-10-31
Additional Resources
- Acxiom and ValueAct Capital Reach Agreement; ValueAct Capital Terminates Proxy Solicitation; Managing Partner to Join Acxiom Board
- LITTLE ROCK, Ark. & SAN FRANCISCO -- Acxiom Corporation (Nasdaq: ACXM) and ValueAct CapitalR today announced that they have reached an agreement under which ValueAct Capital Managing Partner Jeffrey W. Ubben will join the Acxiom board of directors. The agreement ends ValueAct Capital's attempt to elect its three-person alternative slate,...
- Research articles 2006-08-07
- TriZetto Files Registration Statement for ValueAct Capital Shares; 50% of Shares Subject to Lock-Up Agreement
- NEWPORT BEACH, Calif. -- The TriZetto Group, Inc. (Nasdaq: TZIX) announced today that it has filed an S-3 registration statement to register six million shares of TriZetto common stock currently held by ValueAct Capital, pursuant to demand registration rights provided to it in connection with TriZetto's sale of these shares...
- Research articles 2006-02-14
- Acxiom Acknowledges Receipt of ValueAct Capital Letter
- LITTLE ROCK, Ark. -- AcxiomR Corporation (Nasdaq:ACXM) today confirmed that it has received a letter from ValueAct Capital indicating that ValueAct Capital is prepared to present an offer to acquire all outstanding shares of Acxiom common stock it does not already own at a purchase price of $23.00 per share....
- Research articles 2005-06-06
- ValueAct Capital Comments on Acxiom's Rejection of Its Sweetened, All-Cash, Premium Offer
- SAN FRANCISCO -- ValueAct Capital today issued the following statement regarding today's announcement that the Acxiom Corporation Board of Directors had rejected ValueAct's sweetened, $25 per share all-cash offer to acquire all shares of Acxiom (Nasdaq: ACXM) ("Acxiom" or the "Company") that it does not already own. ValueAct Capital is...
- Research articles 2005-12-20
- ValueAct Capital Launches Acxiom-Related Website, www.ChangeAtAcxiom.com, in Support of Its Effort to Elect Three ValueAct Nominees to Acxiom's Board
- SAN FRANCISCO -- ValueAct Capital today announced that it has launched a new website in support of its effort to elect three ValueAct Capital nominees -- Jeffrey W. Ubben, Louis J. Andreozzi and J. Michael Lawrie -- to the Board of Directors of Acxiom Corporation at Acxiom's 2006 Annual Meeting...
- Research articles 2006-07-20
- ValueAct Capital Increases Offer to Acquire Acxiom to $25 Per Share
- SAN FRANCISCO -- ValueAct Capital today increased to $25 per share, from $23 per share, its previously announced all-cash offer to acquire all shares of Acxiom Corporation (Nasdaq: ACXM) ("Acxiom" or the "Company") that it does not already own. ValueAct Capital is Acxiom's largest shareholder, with an approximately 11.75 percent...
- Research articles 2005-10-24
- ValueAct Capital to Vote against Novartis Acquisition of Chiron
- SAN FRANCISCO & BOSTON -- ValueAct Capital said today that it has filed an SEC Form 13-D indicating its intention to vote against the proposed acquisition by Novartis AG of the 56 percent of Chiron Corporation (Nasdaq: CHIR) that Novartis does not already own. The sale of Chiron to Novartis...
- Research articles 2005-12-20
- ValueAct Capital Notifies Acxiom of Its Intent to Nominate Directors
- SAN FRANCISCO -- ValueAct Capital today announced that it has notified Acxiom Corporation of its intention to nominate three candidates for election to the Acxiom Board of Directors at the company's 2006 Annual Meeting of Stockholders. The three director candidates are Jeffrey W. Ubben, Louis J. Andreozzi and J. Michael...
- Research articles 2006-04-03
- Acxiom Agrees to Be Acquired by Silver Lake and ValueAct Capital for $3.0 Billion
- LITTLE ROCK, Ark. -- Acxiom([R]) Corporation (Nasdaq: ACXM)(www.acxiom.com) announced today that it has entered into a definitive agreement to be acquired by Silver Lake, the leading investment firm focused on large-scale investments in technology-driven growth industries, and ValueAct Capital, one of the largest investment firms that makes strategic block and...
- Research articles 2007-05-16
- Acxiom® Responds to ValueAct Capital's Proposal
- LITTLE ROCK, Ark. -- Acxiom Corporation (Nasdaq: ACXM) today announced that the Company's Board of Directors has completed its evaluation of ValueAct Capital's proposal to negotiate an acquisition of the Company, as set forth in its letter dated July 12, 2005. Based on the board's evaluation of this proposal, and...
- Research articles 2005-07-20
- ValueAct Capital Again Refuses to Meet with Chiron, Condemns Its Use of Scare Tactics to Win Support for Novartis Offer
- SAN FRANCISCO & BOSTON -- ValueAct Capital today announced that it has declined a second request by Chiron Corporation (Nasdaq: CHIR) to accept a meeting as part of the company's roadshow aimed at convincing Chiron shareholders to support Novartis AG's $45 per share offer for the 56 percent of Chiron...
- Research articles 2006-03-20
- ValueAct Capital to Vote Its Chiron Shares in Favor of Revised Novartis Merger Agreement
- SAN FRANCISCO and BOSTON -- ValueAct Capital today announced its intention to vote for the amended merger agreement under which Novartis AG would acquire, for $48.00 per share, the 56 percent of Chiron Corporation it does not already own.
- Research articles 2006-04-03
- TriZetto Completes Purchase Of Shares From IMS, Placing 6.6 Million With ValueAct Capital And 5.5 Million Into Treasury
- NEWPORT BEACH, Calif. -- The TriZetto Group, Inc. (Nasdaq:TZIX) announced that yesterday, it completed the purchase of all of the 12,142,857 shares of TriZetto common stock held by IMS Health Incorporated (NYSE:RX) for $6.75 per share. TriZetto will hold 5,542,857 shares as treasury stock, and has placed the remaining 6,600,000...
- Research articles 2004-12-22
- ValueAct Capital Sends Letter Responding to Recent Statements by Acxiom Chairman and Chief Executive Charles D. Morgan
- SAN FRANCISCO -- ValueAct Capital Managing Partner Jeffrey W. Ubben today sent a letter to Charles D. Morgan, Chairman and Chief Executive of Acxiom Corporation, responding to certain statements contained in a letter from Mr. Morgan to Mr. Ubben dated June 21, which letter, along with another Acxiom statement, were...
- Research articles 2006-06-23
- J. Michael Lawrie, Formerly of Siebel Systems and IBM, Joins ValueAct Capital
- SAN FRANCISCO & BOSTON -- ValueAct Capital today announced the appointment of J. Michael Lawrie as a Partner of the firm. Mr. Lawrie was most recently Chief Executive Officer of Siebel Systems, Inc., and previously held senior sales, distribution, marketing and other positions at IBM for more than a quarter-century.
- Research articles 2005-11-10
- Acxiom® Acknowledges Receipt of ValueAct Capital Letter
- LITTLE ROCK, Ark. -- AcxiomR Corporation (Nasdaq: ACXM) today confirmed that it has received a letter from ValueAct Capital offering to acquire all outstanding shares of Acxiom common stock it does not already own at a purchase price of $23.00 per share. The Acxiom Board of Directors will review the...
- Research articles 2005-07-13
- ValueAct Capital Refuses to Meet with Chiron Directors Except to Discuss Ways to Increase Shareholder Value beyond $45
- SAN FRANCISCO & BOSTON -- ValueAct Capital today reiterated its strong opposition to the proposed acquisition by Novartis AG, for $45 per share, of the 56 percent of Chiron Corporation (Nasdaq: CHIR) that Novartis does not already own, and said it would not meet with Chiron directors except to discuss...
- Research articles 2006-03-15
- ValueAct Capital to Launch Cash Tender Offer at $25 Per Share for up to Approximately 7 Million Shares of Acxiom If Its Board Slate is Elected
- SAN FRANCISCO -- ValueAct Capital today announced that it will conduct a tender offer to acquire up to approximately 7 million shares of Acxiom Corporation common stock, at a price of $25 per share in cash, if its nominees are elected to Acxiom's Board of Directors at the Company's 2006...
- Research articles 2006-06-21
- << Previous
- page 1 of 1
- Next >>
